公开(公告)号：US20160060273A1

公开(公告)日：2016-03-03

申请号：US14775265

申请日：2014-03-13

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shizuo KASAI ,  Masaki OGINO ,  Ryo MIZOJIRI ,  Takeshi YAMASAKI ,  Hideki HIROSE ,  Nobuyuki TAKAKURA ,  Tohru YAMASHITA ,  Sachie MORIMOTO ,  Takashi NAKAHATA ,  Asato KINA

IPC: C07D498/10

CPC classification number: C07D498/10

Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

Abstract translation: 提供具有下式（1）表示的化合物或其盐，其具有SSTR5拮抗作用：其中每个符号具有与说明书中相同的定义。

公开(公告)号：US20220388995A1

公开(公告)日：2022-12-08

申请号：US17550173

申请日：2021-12-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji KIMURA ,  Masaki OGINO ,  Yasuhisa KOHARA ,  Tomoko OHASHI ,  Tomohiro KAKU ,  Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO

IPC: C07D409/12 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18 ,  C07D401/12

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20210139491A1

公开(公告)日：2021-05-13

申请号：US16622632

申请日：2018-06-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kazuaki TAKAMI ,  Masaki SETO ,  Shinobu SASAKI ,  Haruhi ANDO ,  Masaki OGINO ,  Tomoko OHASHI ,  Toshihiro IMAEDA ,  Ikuo FUJIMORI ,  Yasuhiro TSUKIMI ,  Masami YAMADA ,  Kenichiro SHIMOKAWA ,  Takeshi WAKABAYASHI ,  Masataka MURAKAMI ,  Makoto FUSHIMI ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Tomohiro OHASHI ,  Hideo SUZUKI ,  Hironobu MAEZAKI ,  Ayumu SATO ,  Yasutomi ASANO ,  Steve SWANN

IPC: C07D491/048 ,  A61K31/4355 ,  A61P1/10

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20200231579A1

公开(公告)日：2020-07-23

申请号：US16634402

申请日：2018-07-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji KIMURA ,  Masaki OGINO ,  Yasuhisa KOHARA ,  Tomoko OHASHI ,  Tomohiro KAKU ,  Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO

IPC: C07D409/12 ,  C07D231/56 ,  C07D235/06 ,  C07D401/12 ,  C07D249/18 ,  A61K9/48 ,  A61K9/20 ,  A61P25/06 ,  A61P25/24 ,  A61P25/28

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20180162850A1

公开(公告)日：2018-06-14

申请号：US15735418

申请日：2016-06-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro SUGIMOTO ,  Shinkichi SUZUKI ,  Hiroki SAKAMOTO ,  Masami YAMADA ,  Minoru NAKAMURA ,  Makoto KAMATA ,  Kenichiro SHIMOKAWA ,  Masaki OGINO ,  Eiji KIMURA ,  Masataka MURAKAMI ,  Jinichi YONEMORI ,  Takuto KOJIMA

IPC: C07D413/14 ,  C07D413/10 ,  C07D265/22 ,  C07D417/10 ,  C07F7/08 ,  C07D491/107 ,  A61P25/28

CPC classification number: C07D265/22 ,  A61P25/28 ,  C07B2200/07 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D413/14 ,  C07D417/06 ,  C07D417/10 ,  C07D471/04 ,  C07D491/107 ,  C07F7/02 ,  C07F7/0814

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.